---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-087375"
form_type: "8-K"
ticker: "RYTM"
cik: "0001649904"
company_name: "RHYTHM PHARMACEUTICALS, INC."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T08:32:52.687986+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Rhythm Pharma amends exec comp; CEO base $717k, severance enhanced for change of control

## Summary
- CEO Meeker: base salary $717,254, bonus target 65%, severance 12 months (18 months +150% bonus on change in control).
- CFO Smith: base $480,000, bonus 40%, severance 9 months (12 months +100% bonus under change in control).
- CTO Shulman ($435,000) and EVP Chien ($473,000) receive similar amended terms.
- Severance conditioned on release of claims and continued compliance with restrictive covenants.
- 280G best-pay provision ensures after-tax maximization if excise tax applies.

## SEC filing metadata
- accession: 0001104659-23-087375
- form_type: 8-K
- ticker: RYTM
- cik: 0001649904
- company_name: RHYTHM PHARMACEUTICALS, INC.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649904/000110465923087375/0001104659-23-087375-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649904/000110465923087375/tm2322430d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-087375
- JSON: https://secwatch.observer/filing/0001104659-23-087375.json
- Plain text: https://secwatch.observer/filing/0001104659-23-087375.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.